Cancer Immunotherapy and Biomarkers

This paper develops a PD-1-iRGD conjugate that enhances antitumor efficacy by improving T cell engagement and penetration, and expands a unique population of CD8+ T cells in the tumor microenvironment.

The paper constructs immune-specific gene sets using non-negative matrix factorization on bulk RNA-seq data to improve immune subtype analysis and ICB response prediction.

This study compares the effectiveness of X-ray and proton irradiation combined with anti-PDL1 immunotherapy in two murine oral cancer models, finding greater synergy with protons.

The paper uses single-cell RNA sequencing to identify molecular pathways and immune subsets in immune-related myocarditis and myositis, finding clonally expanded CD8+ T cells and specific myeloid cell populations associated with adverse outcomes.

This study examines the relationship between immune cell infiltration patterns and survival outcomes in lung adenocarcinoma patients using TCGA data.

This study shows that IL-3 enhances anti-tumor immunity by promoting CTL-basophil interactions, improving CTL activity and tumor suppression.

This study performs a transcriptome-wide meta-analysis to identify determinants of immune checkpoint blockade response, finding that stromal factors, not cancer-cell intrinsic features, are key predictors across tumor types.

This study introduces a next-generation immunocytokine, LH05, which shows improved antitumor effects in cold tumors with reduced toxicity compared to wild-type anti-PD-L1/IL-15.

This study demonstrates that engineered myeloid cells expressing a PD-1-based CAR-like receptor can recognize and attack PD-L1+ solid tumors, enhancing phagocytosis and slowing tumor growth in vivo.

The paper investigates LOY in TME leukocytes, finding higher LOY frequency in Tregs and its association with immune checkpoint receptor expression.

This study identifies Pccb as a regulator of anti-tumor T cell activity in pancreatic cancer, showing that its deletion impairs T cell function and that PD-L1/PD1 blockade can restore T cell activity.

The paper identifies immune landscape differences in responders and non-responders to anti-PD-1 therapy in head and neck cancers using spatial mapping.

This paper identifies three TIDE subtypes in bladder and pan-cancers, showing their prognostic and immunotherapeutic significance through transcriptome analysis and validation with real-world samples.

This study develops a transcriptome-based classifier to predict CD8+ T cell spatial infiltration patterns in the tumor microenvironment and shows its prognostic and predictive value across clinical trials.

This study shows PVRL2 suppresses anti-tumor immunity independently of PVRIG and TIGIT, with deletion reducing tumor growth more than PD-L1 loss.

This paper develops a mouse model to study CPI-hepatitis and shows that inhibiting CCR2+ monocyte recruitment prevents liver damage caused by checkpoint inhibitors.

This study shows that Acod1 in cancer cells promotes immune evasion by releasing inhibitory peptides, not ITA, and that reducing Acod1 can make tumors responsive to PD-1 therapy.

The paper uses single RNA molecule resolution imaging to analyze immunotherapy response in triple negative breast tumors with tertiary lymphoid structures, identifying two tumor types based on immune infiltration and their differential responses to pembrolizumab and radiation therapy.

The paper uses a cholesterol PET radiotracer to predict immunotherapy response in TNBC mouse models by measuring T cell cholesterol uptake.

The paper detects neoantigen-reactive CD8+ T cells in tumor biopsies and peripheral blood post-checkpoint blockade therapy and identifies peptide hydrophobicity and treatment-induced phenotypes as factors influencing their response.

This study investigates how co-culture affects T cell motility and cancer-T cell interactions, finding that specific T cells show increased contact time and directional persistence, while cancer cells develop distinct subpopulations with immunosuppressive and antigen-presenting properties.

The paper shows that long-lasting mRNA-encoded IL2 restores immune responses in MHC class I-deficient cancers by activating neoantigen-specific CD8+ T cells.

The paper introduces a bioinformatics pipeline to identify known and putative immune inhibitory receptors as therapeutic targets using machine learning and transcriptomics data.

RIGATonI identifies genomic alterations in tumors affecting lymphocyte infiltration using machine learning and integrates immune phenotype and function predictions.

This study identifies GFPT2 as a metabolic checkpoint in EGFR-mutated NSCLC that promotes immune evasion, and shows that targeting GFPT2 enhances PD-1 blockade therapy.

This study analyzes plasma proteomic changes in NSCLC patients on immunotherapy to identify biomarkers of treatment response and resistance.

The paper analyzes TILs in GBM using CITE-seq and scRNA-seq to show that CD8+ T cells are predominantly clonally expanded GZMK+ effector cells, lacking canonical exhaustion.

The paper develops an antigen-specific assay for T cell exhaustion and identifies IKAROS as a driver of exhaustion, showing that iberdomide prevents exhaustion by blocking chromatin remodeling.

This study uses machine learning to analyze spatial proteomic data from pancreatic cancer patients, linking T cell function and localization to neoadjuvant CD40 therapy and clinical outcomes.

The paper identifies a set of endogenous retroviruses (ERVs) whose expression predicts survival in multiple cancers and is linked to immune response signatures.